The journal, Brain, highlights a recent paper on "Genetic topography and cortical cell loss in Huntington's disease link development and neurodegeneration". A review by Schultz et al., succinctly summarizes intriguing…
The journal, Brain, highlights a recent paper on "Genetic topography and cortical cell loss in Huntington's disease link development and neurodegeneration". A review by Schultz et al., succinctly summarizes intriguing…
HD-CARE supports the UCI Thompson Lab, which is located in the UCI Sue and Bill Gross Stem Cell Research Center (SCRC). The SCRC thanked us for making 2023 an incredible…
Exciting new collaboration between the Huntington's Study Group (HSG) and Roche therapeutics. HSG will advise Roche on recruitment and enrollment of the needs of GENERATION HD2. This work will collectively…
SAGE therapeutics is a biopharmaceutical company with the mission of improving brain health. On 11/13/23, SAGE announcted that the US Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD)…
The Huntington Study Group (HSG) shared that the Phase 3 KINECT-HD study resulted in FDA approval of valbenazine for treatment of chorea in Huntington's disease (HD). As a vesicular monoamine…
Register today! HD-Care invites you to our summer fundraiser on Saturday September 30, 2023 1-4pm at Campus Jax. Live music and "Live Ask" opportunity to support HD research and patient…
In the UCI MIND quarterly newsletter, HD-CARE is celebrated as 10 years as a non-profit organization! Check out the article along with other exciting news from UCI: https://mind.uci.edu/mind-matters-quarterly-newsletter-winter-2023/
From Huntington Study Group: Prilenia Therapeutics B.V., a clinical stage biotechnology company, met a milestone that the last participant in PROOF-HD, a global Phase 3 study in Huntington’s disease (HD),…
30 years ago, the Huntington's Disease Collaborative Research Group identified the Huntington's disease (HD) mutant gene. By examining 75 disease families, they found a trinucleotide (CAG) repeat that is expanded…
We are devastated to learn that a member of our community and Director of Patient Advocacy of the California Institute of Regenerative Medicine (CIRM), Kevin McCormack, passed away three months…